アリムラ　ケン   ARIMURA Ken   有村　健    所属   医学部 医学科（東京女子医科大学病院）    職種   講師
論文種別	原著
言語種別	英語
査読の有無	査読なし
表題	Nationwide trends in utilization and expenditure of biologic agents approved for asthma in Japan: Insights from the national database (2014-2023).
掲載誌名	正式名：Respiratory investigation 略　 称：Respir Investig ISSNコード：22125353/22125345
掲載区分	国外
巻・号・頁	63(5),pp.915-917
著者・共著者	Tomohiro Akaba†, Mitsuko Kondo, Osamitsu Yagi, Keiko Kan-O, Ken Arimura, Atsushi Kurokawa, Yuno Shiota, Naoko Arakawa, Yutaro Horie, Musashi Ueda, Etsuko Tagaya
発行年月	2025/07
概要	Biologics have transformed the management of severe asthma; however, nationwide data on their use in Japan remain limited. We conducted a descriptive analysis using the NDB Open Database from fiscal years 2014-2023 to examine trends in the prescription volumes and costs for five approved biologics. Total prescriptions increased markedly from 81 450 in 2014 to >2 million in 2023, while total costs rose from 24.1 million to 973.3 million U.S. dollars. The proportion of outpatient self-injection prescriptions accounted for more than half of the prescriptions by 2023. These findings reflect the broader adoption of biologics supported by biomarker-driven treatment and expanded access through home administration. Although biologics offer clinical benefits, their growing use highlights the need to monitor their long-term costs and ensure their appropriate utilization. This study provides a nationwide overview of the biologics approved for asthma treatment and highlights key trends relevant to clinicians and policymakers.
DOI	10.1016/j.resinv.2025.07.012
PMID	40716196